Navigation Links
BusinessWeek Article Highlights Promising Breakthrough Treatment,for Advanced Coronary Artery Disease

WAKEFIELD, Mass.--(BUSINESS WIRE)--Jul 10, 2007 - BusinessWeek published an article on July 6 discussing the race by pharmaceutical and biotechnology companies to be first to bring to market an effective angiogenesis treatment for cardiovascular disease. While angiogenesis therapies are being pursued by Sanofi-Aventis, Boston Scientific, Baxter, and Genzyme, among others, the article highlights a very promising new biological therapy for advanced coronary artery disease (CAD) patients, FGF-1, from CardioVascular BioTherapeutics Inc. (CVBT).

BusinessWeek cites The Bruckner Group's (BGI) study presenting the preliminary value proposition for FGF-1 use in advanced coronary artery disease patients. According to BGI's study, FGF-1 has the potential to reduce treatment costs of advanced CAD patients by 20% over a five-year period after treatment.

Here is a link to the article:

"It's exciting when a breakthrough treatment appears with the potential to transform how we treat patients with a serious and costly disease like coronary artery disease," said Michael Russo, Partner, The Bruckner Group. "Typically, breakthrough treatments add cost to the healthcare system. BGI's study indicates, however, that FGF-1 could actually reduce total treatment costs, by as much as 20% over five years. We are looking forward to gathering evidence from the ongoing clinical trials to conclusively prove these points," Russo said.

According to Daniel Montano, CEO of CardioVascular BioTherapeutics, "The Bruckner Group's ongoing development of FGF-1's value proposition has been critical to FGF-1's commercial development. BGI's findings are allowing CVBT to have meaningful discussions with payers and employers. We are telling them that not only is a clinical breakthrough on the horizon that has the potential to revolutionize treatment for coronary artery disease patients, but more importantly, it will produce great savings. Given the growing financial strains on the U.S. healthcare system, our message is being met with great enthusiasm by payers, employers, and other stakeholders," Montano said.

About The Bruckner Group (BGI):

The Bruckner Group provides strategic advice to pharmaceutical and biotechnology executives. BGI is the leading expert in healthcare value strategy, helping pharmaceutical and biotechnology companies enhance and maximize the healthcare value of new therapies in development, prove that value at launch to payers and other stakeholders, and leverage that value post-launch to dominate markets.


The Bruckner Group
David Balekdjian, Partner, 781-245-4454


Related medicine technology :

1. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
2. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
3. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
4. Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma
5. Expert Opinion Highlights Avigens AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal
6. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
7. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
8. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
9. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
10. Presentations at 2007 European Stroke Congress Highlights New Direction for Viprinex (ancrod)
11. Data to be Presented at ASCO 2007 Highlights sanofi-aventis Commitment to Cancer Care and Research
Post Your Comments:
(Date:11/26/2015)... 2015 --> ... combineert immunotherapie met Bremachlorin-photodynamische therapie voor de ... ) --> ... ) Uit een ... (LUMC) blijkt dat ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "2016 Future Horizons ... of Abuse Testing Market: Supplier Shares, Country ... report to their offering. --> ... the "2016 Future Horizons and Growth ...
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Therapeutic Drug Monitoring (TDM) Market: Supplier ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare ... participated in the 61st annual Employee Benefits Conference. The Employee Benefits Conference was ... November 8th through Wednesday, November 11th, 2015. The conference was held at the ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... has collaborated with Women’s Web – an online resource for Indian women ... mental and emotional well-being relationship, life balance, stress, professional development, and lifestyle. ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... more aggressive than those found on mammography, according to a study published online ... additional cancers not seen on mammography may necessitate a change in treatment. , ...
(Date:11/25/2015)... ... November 25, 2015 , ... The holiday season ... and pleasing the palates of attendees is of the utmost importance. Whether you ... seasonal get-together, give these recipes a try this holiday season. , Turkey Croquettes ...
(Date:11/25/2015)... ... November 25, 2015 , ... Medical Solutions, one ... for its stellar workplace culture with the company’s Cincinnati office being named a ... Cincinnati office was named a finalist in Cincinnati Business Courier’s 13th annual Greater ...
Breaking Medicine News(10 mins):